Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human endostatin plus lattice radiotherapy for advanced thoracic tumors (single-arm phase 2)
ChiCTR2600120829Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in thoracic cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
thoracic cancer
Beyond the preview
Go deeper on ChiCTR2600120829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120829.